By the Mindtek Research team · Scientifically reviewed · ~5 min read
NAD⁺ (nicotinamide adenine dinucleotide) is a coenzyme central to energy metabolism and to the activity of sirtuins and PARPs. Tissue NAD⁺ declines with age in multiple species, which motivated interest in precursors that can restore it (Rajman, Chwalek & Sinclair, 2018). Two dominate the conversation: nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR). This note compares their mechanisms and human evidence — educational, research-use framing only.
Same destination, different routes
NR is phosphorylated to NMN by the nicotinamide riboside kinases (NRK1/2), then converted to NAD⁺. NMN sits one step further along that salvage pathway. A live mechanistic question is how NMN enters cells: a dedicated transporter (Slc12a8) has been reported (Grozio et al., 2019), while other work argues NMN is first dephosphorylated to NR at the cell surface. Inference: in practice both precursors raise intracellular NAD⁺ — the debate is about the path, not the destination.
What human studies actually show
NR: orally bioavailable and raises blood NAD⁺ in humans (Trammell et al., 2016); chronic supplementation elevated NAD⁺ and was well tolerated in middle-aged and older adults (Martens et al., 2018). NMN: improved skeletal-muscle insulin sensitivity in prediabetic women in a randomised trial (Yoshino et al., 2021). Data vs gap: both reliably increase NAD⁺ markers; rigorous head-to-head outcome comparisons remain scarce.
The honest read: strong biomarker evidence that both raise NAD⁺, with clinical-outcome data still maturing.
Formulation matters as much as the molecule
Route, stability and purity shape how much precursor actually reaches tissue. Our team was among the first in Southeast Asia to deliver IV NMN and NR — work we credit to the lab and cold-chain team rather than any single molecule. For research and formulation questions, batch-verified material with a certificate of analysis is the starting point.
References. Rajman L, Chwalek K, Sinclair DA. Therapeutic potential of NAD-boosting molecules: the in vivo evidence. Cell Metab, 2018. · Trammell SAJ, et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun, 2016. · Martens CR, et al. Chronic NR supplementation elevates NAD⁺ in healthy older adults. Nat Commun, 2018. · Yoshino M, et al. NMN increases muscle insulin sensitivity in prediabetic women. Science, 2021. · Grozio A, et al. Slc12a8 is a nicotinamide mononucleotide transporter. Nat Metab, 2019.
For research and educational use only. Not medical advice; not for human consumption. We do not stock these in common retail forms, but given the research case and volume we can source or produce batch-verified custom blends. No therapeutic claims are made.